stockrow
Saturday 7 November 2026
Export GERN’s income statement to Excel — free account
Geron Corporation
GERN Healthcare Biotechnology
Geron Corporation’s revenue for fiscal 2025 (year ended December 2025) was $183.9 million, up 138.8% from fiscal 2024.
- Revenue
- +27.5%
- EPS
- +106.7%
- Free cash flow
- +176.1%
- Total debt
- +0.99%
Quarter to September 2026, against a year earlier
0.98
0.03
+3.16%
Follow GERN
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| (20.12%) | (28.28%) | (27.07%) | (32.99%) |
+8 more TTM periods Free account |
|
Piotroski F-Score |
4 | 3 | 3 | 3 | |
| (8.74%) | (12.59%) | (12.28%) | (14.34%) | ||
ROIC |
(34.12%) | (89.85%) | (93.28%) | 0.00% | |
Return on Tangible Assets |
(12.09%) | (16.21%) | (15.80%) | (20.39%) | |
Average Days of Receivables |
80.56 | 95.47 | 82.07 | 77.86 | |
Free Cash Flow per Share |
(0.14) | (0.17) | (0.19) | (0.17) | |
Free Cash Flow |
(91.16) | (114.76) | (126.30) | (111.09) | |
Capital Expenditures |
(0.63) | (0.39) | (0.33) | (0.05) | |
| Other line items | |||||
Cash ROIC |
(14.34%) | (17.89%) | (19.04%) | (15.75%) | |
Accounts Receivable Turnover |
5.08 | 4.41 | 5.02 | 4.71 | |
Accounts Payable Turnover |
1.38 | 1.56 | 0.50 | 0.48 | |
Inventory Turnover |
0.16 | 0.14 | 0.06 | 0.06 | |
Average Days of Payables |
308.62 | 241.99 | 887.56 | 865.92 | |
Days of Inventory on Hand |
2,526.66 | 3,396.99 | 9,300.28 | 8,972.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
29.07% | 35.00% | 36.36% | 38.85% | |
Selling, General and Administrative Expense of Revenue |
69.72% | 75.75% | 78.86% | 86.61% | |
Share Based Compensation of Revenue |
9.41% | 10.96% | 12.36% | 14.55% | |
Interest Coverage |
(1.11) | (1.71) | (1.64) | (2.10) | |
Operating CF/Net income |
1.89 | 1.69 | 1.87 | 1.33 | |
Depreciation/Fixed assets |
(1.14) | (2.17) | (3.45) | (5.26) | |
Capex/Depreciation |
0.50 | 0.16 | 0.10 | 0.01 | |
Revenue per Share |
0.32 | 0.31 | 0.29 | 0.28 | |
Operating CF per Share |
(0.13) | (0.17) | (0.19) | (0.17) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026